Linagliptin

Linagliptin works by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises levels of the incretin hormones GLP‑1 and GIP, which stimulate insulin release and suppress glucagon secretion in a glucose‑dependent manner, thereby lowering blood sugar levels.

The prescribed dose of linagliptin is individualized by the treating physician. It is commonly administered as a once‑daily tablet, and the exact amount may be adjusted based on the patient’s clinical response, renal function, and overall treatment goals.

Safety of linagliptin during pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order linagliptin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its primarily hepatic elimination, which means dose adjustment is not required in renal impairment. This pharmacokinetic profile can simplify treatment in patients with reduced kidney function compared with some alternatives.

Linagliptin tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Linagliptin is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include pancreatitis, which may present as severe abdominal pain, and severe hypersensitivity reactions such as angioedema or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal discomfort, rash, or swelling of the face or throat.

Linagliptin should be avoided in patients with a known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with a history of pancreatitis, severe hepatic impairment, or those who are pregnant or breastfeeding without a clear medical indication.